Cardiopulmonary exercise testing and haemodynamics in patients with chronic obstructive pulmonary disease

Cardiopulmonary exercise testing and haemodynamics in patients with chronic obstructive pulmonary disease: an observational cross-sectional study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN18993812

Enrollment

100

Registered

2008-11-20

Start date

2009-04-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease (COPD) Respiratory Other chronic obstructive pulmonary disease

Interventions

Patients suffering from COPD (according to the GOLD criteria classified as stage III and IV) will undergo CPET according to a standardised exercise protocol. In addition to the previous obtained spiro

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of COPD (according to American Thoracic Society [ATS] case definition) meeting all necessary criteria to be classified as Global Initiative for chronic Obstructive Lung Disease (GOLD) III and IV 2. Informed consent for study-related procedure 3. Stable medications for the last two weeks 4. Ability to safely perform the CPET without contraindications 5. Aged 18 - 80 years, both genders

Exclusion criteria

Exclusion criteria: 1. Existing contraindication for exercise test 2. Patients with clinically relevant congestive heart failure or other diseases which may influence the results of the study (e.g. handicaps) 3. Exacerbation of COPD within the last two weeks before CPET 4. Conditions associated with poor compliance 5. Patients who have participated in a clinical study within the last four weeks

Design outcomes

Primary

Measure	Time frame
1. Exercise variables 2. Lung function data 3. Haemodynamic measures obtained by right heart catheterisation Primary and secondary outcomes will be assessed at the end of the study.	—

Secondary

Measure	Time frame
1. GOLD stage 2. Mortality Primary and secondary outcomes will be assessed at the end of the study.	—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026